The BMJ brings you interviews with the people who are shaping medicine and science around the world.
…
continue reading
Content provided by ReachMD. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by ReachMD or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!
Go offline with the Player FM app!
DEARA Versus SOC in FSGS Management: Clinical Trial Insights
MP3•Episode home
Manage episode 516781677 series 3128163
Content provided by ReachMD. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by ReachMD or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
CME credits: 1.00
Valid until: 19-09-2026
Claim your CME credit at https://reachmd.com/programs/cme/deara-versus-soc-in-fsgs-management-clinical-trial-insights/37188/
Managing patients with focal segmental glomerulosclerosis, or FSGS, can present certain challenges. FSGS is a serious, progressive condition that has no current FDA-approved treatment and standard of care therapy may not meet treatment goals for many patients. But the current use of patient-reported outcomes (PROs), as well as emerging treatments on the horizon, may prove to be valuable tools in shaping the future of FSGS care.
…
continue reading
Valid until: 19-09-2026
Claim your CME credit at https://reachmd.com/programs/cme/deara-versus-soc-in-fsgs-management-clinical-trial-insights/37188/
Managing patients with focal segmental glomerulosclerosis, or FSGS, can present certain challenges. FSGS is a serious, progressive condition that has no current FDA-approved treatment and standard of care therapy may not meet treatment goals for many patients. But the current use of patient-reported outcomes (PROs), as well as emerging treatments on the horizon, may prove to be valuable tools in shaping the future of FSGS care.
407 episodes
MP3•Episode home
Manage episode 516781677 series 3128163
Content provided by ReachMD. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by ReachMD or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
CME credits: 1.00
Valid until: 19-09-2026
Claim your CME credit at https://reachmd.com/programs/cme/deara-versus-soc-in-fsgs-management-clinical-trial-insights/37188/
Managing patients with focal segmental glomerulosclerosis, or FSGS, can present certain challenges. FSGS is a serious, progressive condition that has no current FDA-approved treatment and standard of care therapy may not meet treatment goals for many patients. But the current use of patient-reported outcomes (PROs), as well as emerging treatments on the horizon, may prove to be valuable tools in shaping the future of FSGS care.
…
continue reading
Valid until: 19-09-2026
Claim your CME credit at https://reachmd.com/programs/cme/deara-versus-soc-in-fsgs-management-clinical-trial-insights/37188/
Managing patients with focal segmental glomerulosclerosis, or FSGS, can present certain challenges. FSGS is a serious, progressive condition that has no current FDA-approved treatment and standard of care therapy may not meet treatment goals for many patients. But the current use of patient-reported outcomes (PROs), as well as emerging treatments on the horizon, may prove to be valuable tools in shaping the future of FSGS care.
407 episodes
All episodes
×Welcome to Player FM!
Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.